Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial
-
By
-
March 18, 2026
Objective:
To evaluate the prognostic performance of a previously developed multivariable risk score for predicting cardiorenal outcomes in high-risk type 2 diabetes patients with established cardiovascular disease.
Key Findings:
- The risk score showed strong associations with cardiorenal outcomes, with higher DKD incidence in higher risk groups (52.5% vs. 13.5% in very high- vs. low-risk), indicating a significant need for targeted interventions.
- Progressive increases in renal disease progression events were observed across risk strata, emphasizing the importance of early identification.
- The high/very high-risk group had significantly greater risks of MACEs (15.2% vs. 6.8%) and HF (2.8% vs. 0.5%) compared to the low-risk group, highlighting the critical need for monitoring.
Interpretation:
The risk score effectively identifies high-risk T2D patients for early intervention, highlighting the importance of integrated cardiorenal risk assessment.
Limitations:
- The analysis is based on a post-hoc evaluation, which may introduce biases that could affect the reliability of the findings.
- The study population was limited to those with established cardiovascular disease, potentially affecting the generalizability of the results to broader T2D populations.
Conclusion:
The simplified clinical score is a practical tool for identifying high cardiorenal risk in T2D patients, facilitating timely interventions to improve outcomes.
